

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

The following listing of claims replaces all prior versions, and listings, of claims in the application.

1.-20. (Canceled)

21. (Currently Amended) An isolated polypeptide selected from the group consisting of:

- a) a polypeptide comprising an amino acid sequence of SEQ ID NO:17,
- b) a polypeptide comprising ~~a naturally occurring an~~ amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:17 and having decreased expression in leukemia, lymphoma and prostate tumor cells, and
- c) an immunogenic fragment of a polypeptide consisting of an amino acid sequence of SEQ ID NO:17, wherein said fragment comprises at least 40 contiguous amino acid residues of SEQ ID NO:17.

22. (Previously Presented) An isolated polynucleotide encoding a polypeptide of claim 21.

23. (Previously Presented) An isolated polynucleotide of claim 22 comprising a polynucleotide sequence of SEQ ID NO:44.

24. (Previously Presented) A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 22.

25. (Previously Presented) A cell transformed with a recombinant polynucleotide of claim 24.

26. (Previously Presented) A method of producing a polypeptide of claim 21, the method comprising:

- a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 21, and
- b) recovering the polypeptide so expressed.

27. (Previously Presented) A method of claim 26, wherein the polypeptide comprises an amino acid sequence of SEQ ID NO:17.

28. (Currently Amended) An isolated polynucleotide selected from the group consisting of:

- a) a polynucleotide comprising a polynucleotide sequence of SEQ ID NO:44,
- b) a polynucleotide comprising a ~~naturally occurring~~ polynucleotide sequence at least 90% identical to a polynucleotide sequence of SEQ ID NO:44, and encoding a polypeptide that has decreased expression in leukemia, lymphoma and prostate tumor cells,
- c) a polynucleotide complementary to a polynucleotide of a),
- d) a polynucleotide complementary to a polynucleotide of b), and
- e) an RNA equivalent of a)-d).

29.-30. (Canceled)

31. (Previously Presented) A composition comprising a polypeptide of claim 21 and a pharmaceutically acceptable excipient.

32. (Previously Presented) A composition of claim 31, wherein the polypeptide comprises an amino acid sequence of SEQ ID NO:17.

33.-40. (Canceled)

41. (New) An isolated polypeptide of claim 21 comprising an amino acid sequence at least 95% identical to an amino acid sequence of SEQ ID NO:17 and having decreased expression in leukemia, lymphoma and prostate tumor cells.

42. (New) An isolated polynucleotide of claim 28 comprising a polynucleotide sequence at least 95% identical to a polynucleotide sequence of SEQ ID NO:44, and encoding a polypeptide that has decreased expression in leukemia, lymphoma and prostate tumor cells.